Trial Profile
TAXUS ARRIVE: Taxus peri-approval registry: A multi-center safety surveillance program
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Apr 2017
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary)
- Indications Coronary artery disease; Coronary artery restenosis
- Focus Therapeutic Use
- Acronyms ARRIVE
- Sponsors Boston Scientific Corporation
- 17 Oct 2008 Two-year results from the diabetic subset analysis presented at the Cardiovascular Research Foundation's Transcatheter Cardiovascular Therapeutics symposium.
- 13 May 2008 Pooled analysis of 2-year outcomes for 7,492 patients in the ARRIVE 1 and 2 registries reported at EuroPCR 2008.
- 29 Mar 2008 Pooled analysis of 2-year outcomes for 7,033 patients in the ARRIVE 1 and 2 registries reported at SCAI-ACCi2 2008.